
Psychopharmacology and Psychiatry Updates
Psychopharmacology InstituteAudio
- Format:
- Podcast
- New episodes:
- Weekly
- Typical length:
- about 15 minutes
- Latest episode:
About this show
Practical psychopharmacology updates for mental health clinicians. Useful for psychiatry / mental health professionals. Expert interviews and soundbites from CME presentations. Practical and free of commercial bias. Not sponsored by any pharmaceutical company.
Covers: psychiatry, psychopharmacology, antipsychotic medications, antidepressant treatment, ocd treatment, ptsd treatment, insomnia treatment, addiction medicine
Show details and episodes come from the publisher's public feed at psychopharmacology.libsyn.com. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
This podcast gives mental health clinicians practical updates on psychopharmacology, drawing on expert interviews and presentation excerpts. Recent episodes cover adjunctive antipsychotics for major depression, buprenorphine and methadone in liver disease, catatonia treatment, prazosin for PTSD nightmares, and Z-drugs in early pregnancy.
Cosmos
Similar in subject
- PsychRounds: The Psychiatry Podcast
Both cover: addiction medicine, psychopharmacology, psychiatry - NEI Podcast
Both cover: psychopharmacology, psychiatry
Similar shows
Explore more
Episodes
Which Adjunctive Antipsychotic Is Best for Major Depression?
· 10 min
Faculty: James Phelps, M.D. Host: Flavio Guzmán, M.D. - Learn more about our membership here - Earn 0.5 CMEs: Quick Take Vol. 89 - Which Adjunctive Antipsychotic Is Best for Major Depression?
Not rated yetLiver Disease: Buprenorphine, Methadone, and Smoking Cessation Agents
· 11 min
Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 1.25 CME: Addiction Psychopharmacology in Patients with Medical Comorbidities - Liver Disease: Buprenorphine, Methadone, and Smoking Cessation Agents
Not rated yetCatatonia: Should Antipsychotics Always Be Avoided?
· 14 min
Faculty: Scott R. Beach, M.D. Host: Flavio Guzmán, M.D. - Learn more about our membership here - Earn 0.75 CMEs: Quick Take Vol. 88 - Catatonia: Should Antipsychotics Always Be Avoided?
Not rated yetPrazosin for PTSD Nightmares
· 16 min
In this episode, we explore prazosin for PTSD-related nightmares with Dr. David Osser. He explains why prazosin stands out among alpha-1 blockers, which patients are most likely to respond, and why so many trials failed from underdosing, including how titration differs for men and women. Faculty: David Osser, M.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 1.5 CME: PTSD Psychopharmacology Algorithm - Prazosin for PTSD Nightmares: Dosing Protocols for Men and Women
Not rated yetFirst-Episode Psychosis in Women
· 12 min
Faculty: Amanda Koire, M.D., Ph.D. Host: Flavio Guzmán, M.D. - Learn more about our membership here - Earn 0.5 CMEs: Quick Take Vol. 87 - First-Episode Psychosis in Women: Which Antipsychotic Is the Preferred Choice?
Not rated yetSecond-Generation Antipsychotics for OCD Augmentation
· 9 min
Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 1.25 CME: Treatment-Resistant OCD: From SSRIs to Augmentation - Second-Generation Antipsychotics for OCD Augmentation: Third-Line Agents
Not rated yetAre Z-Drugs Safe in the First Trimester of Pregnancy?
· 17 min
In this episode, we review a JAMA Psychiatry study of over 4 million pregnancies examining first-trimester Z-drug exposure and congenital malformations. Dr. Amanda Koire explains why overall risk wasn't increased, what the neural tube defect signal means, and how to evaluate insomnia before prescribing. Faculty: Amanda Koire, M.D., Ph.D. Host: Flavio Guzmán, M.D. - Learn more about our membership here - Earn 0.75 CMEs: Quick Take Vol. 86 - Are Z-Drugs Safe in the First Trimester of Pregnancy?
Not rated yetGlutamatergic Augmentation in OCD
· 16 min
Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 1.25 CME: Treatment-Resistant OCD: From SSRIs to Augmentation - Glutamatergic Augmentation in OCD: Memantine, Riluzole, Lamotrigine and Other Agents
Not rated yetSchizophrenia: Which of Seven Antipsychotics Wins?
· 15 min
Faculty: Oliver Freudenreich, M.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 0.75 CMEs: Quick Take Vol. 85 - Schizophrenia: Which of Seven Antipsychotics Wins on Acute Efficacy and Safety?
Not rated yetSSRI Dosing for OCD: Beyond FDA Guidelines
· 9 min
Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 1.25 CME: SSRI Dosing for OCD: Beyond FDA Guidelines - Treatment-Resistant OCD: From SSRIs to Augmentation
Not rated yetTrazodone for Insomnia and Comorbid Depression
· 10 min
In this episode, we explore a new meta-analysis reconciling trazodone's real-world reputation with cautious sleep medicine guidelines, examining its effects on sleep architecture and depressive symptoms in patients with comorbid insomnia and depression, alongside its notable side effect profile. Can a decades-old antidepressant be the missing link for restorative sleep? Faculty: Paul Zarkowski, M.D. Host: Flavio Guzmán, M.D. - Learn more about our memberships here - Earn 0.5 CMEs: Quick Take Vol. 85 - Trazodone for Insomnia and Comorbid Depression: Are the AASM Guidelines Relevant?
Not rated yetAntipsychotics, Prolactin, and Sexual Side Effects
· 8 min
In this episode, we explore why antipsychotics cause hyperprolactinemia and sexual side effects, a leading reason patients quietly stop treatment. Dr. Oliver Freudenreich breaks down which medications carry the highest risk, the long-term health implications, and practical strategies for monitoring, switching, or augmenting therapy. Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know - Managing Hyperprolactinemia and Sexual Side Effects from Antipsychotic Use
Not rated yetEMERGENT-5: Cobenfy and Treatment Durability
· 12 min
In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up over time, what side effects persist, and why blood pressure monitoring now deserves a permanent spot on your checklist. Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.5 CME: Quick Take Vol. 85 - Xanomeline-Trospium Long-Term: Does Efficacy and Safety Hold Up After One Year?
Not rated yetAntipsychotics and Weight Gain
· 14 min
In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — why it happens, which medications carry the highest risk, and how to build a proactive ABC strategy using switching, metformin, and emerging GLP-1 agonists to protect your patients' metabolic health. Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know - Antipsychotic-Induced Weight Gain: Prevention and Management
Not rated yetEPA vs. DHA: Fish Oil and Treatment-Resistant Depression
· 12 min
In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-resistant depression. Dr. Derick Vergne breaks down the clinical evidence, dosing, and the anti-inflammatory mechanisms that may explain why EPA outperforms DHA in easing stubborn depressive symptoms. Faculty: Derick E. Vergne, M.D. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 0.75 CMEs: Quick Take Vol. 84 - Eicosapentaenoic Acid: Effective as Adjunctive for TRD?
Not rated yetAUD Medications and Hepatic Safety
· 10 min
In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin Sevarino breaks down a practical algorithm for selecting between naltrexone, acamprosate, disulfiram, and other options, tailored to hepatic function, from early liver disease through decompensated cirrhosis. Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder - Alcohol Use Disorder Algorithm: Medication Selection Based on Liver Status
Not rated yetGLP-1 Agonists in Serious Mental Illness: Current Evidence
· 15 min
In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done? Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.75 CMEs: Quick Take Vol. 84 - GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management?
Not rated yetGabapentin, Topiramate & Baclofen in AUD
· 17 min
In this episode, we explore three off-label but evidence-supported medications — gabapentin, topiramate, and baclofen — for alcohol use disorder, examining their mechanisms, dosing strategies, tolerability challenges, and which patients are most likely to benefit when first-line treatments have failed. Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CMEs: Pharmacotherapy of Alcohol Use Disorder - Gabapentin, Topiramate, and Baclofen for Alcohol Use Disorder
Not rated yetDeprescribing Benzodiazepines: When Tapering Might Do More Harm Than Good
· 17 min
In this episode, we explore the nuanced landscape of benzodiazepine tapering, guided by a major 2024 joint clinical practice guideline. Are we training a generation of psychiatrists too afraid to prescribe one of psychiatry's most effective drug classes? Dr. Scott Beach unpacks the risks, benefits, and clinical realities. Faculty: Scott Beach, M.D. Host: Richard Seeber, M.D. - Learn more about our membership here - Earn 0.75 CMEs: Quick Take Vol. 84 - Benzodiazepine Tapering: Key Takeaways From New Guidelines
Not rated yetDisulfiram Unpacked: Efficacy, Risks, and Liver Safety
· 16 min
In this episode, we explore disulfiram (Antabuse), one of the oldest FDA-approved treatments for alcohol use disorder. Dr. Kevin Sevarino breaks down its mechanism, efficacy data, and critical hepatic safety considerations. Could enforced sobriety be the missing piece for your most treatment-resistant patients? Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D. - Learn more about our memberships here - Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder - Disulfiram for Alcohol Use Disorder: Mechanisms, Efficacy, and Hepatic Safety Considerations
Not rated yet